new
delhi
metalloblactamas
first
report
swedish
patient
recent
studi
report
klebsiella
pneumonia
posit
strain
escherichia
coli
posit
strain
highli
resist
antibiot
test
except
tigecyclin
colistin
longer
reli
treat
infect
therefor
becom
potenti
major
global
health
threat
studi
perform
model
studi
obtain
structur
complex
reveal
hydrolyt
mechan
highli
conserv
addit
detail
analysi
indic
flexibl
hydrophob
togeth
evolut
positivecharg
lead
posit
strain
potent
extens
antibiot
resist
compar
mbl
furthermor
biolog
experi
reveal
molecular
basi
antibiot
catalysi
enzymat
level
found
enzym
highli
potent
degrad
carbapenem
antibiot
mostli
suscept
tigecyclin
abil
slow
hydrolysi
veloc
meropenem
meanwhil
mutagenesi
experi
includ
display
downregul
meropenem
catalysi
prove
accuraci
model
present
effect
antibiot
posit
pathogen
studi
provid
clue
investig
molecular
basi
extend
antibiot
resist
acceler
search
new
antibiot
posit
strain
clinic
studi
new
delhi
metalloblactamas
first
report
swedish
patient
travel
new
delhi
acquir
urinari
tract
infect
caus
klebsiella
pneumonia
recent
studi
report
klebsiella
pneumonia
posit
strain
escherichia
coli
posit
strain
highli
resist
antibiot
test
except
tigecyclin
colistin
sinc
august
spread
dissemin
posit
strain
occur
case
global
report
media
countri
includ
unit
state
canada
sweden
unit
kingdom
austria
belgium
franc
netherland
germani
africa
oman
australia
japan
china
although
case
current
preval
worldwid
spread
renal
bone
marrow
transplant
dialysi
cerebr
infarct
chronic
obstruct
pulmonari
diseas
pregnanc
burn
road
traffic
accid
cosmet
surgeri
addit
posit
strain
destroy
carbapenem
antibiot
meropenem
imipenem
doripenem
ertapenem
break
carbapenem
group
antibiot
serv
basi
treatment
antibioticresist
bacteri
infect
longer
reli
purpos
due
emerg
posit
strain
therefor
spread
pathogen
microorgan
carri
gene
also
call
super
bug
becom
potenti
major
global
health
threat
belong
metalloblactamas
mbl
class
b
famili
contain
zn
dival
cation
cofactor
inactiv
almost
class
blactam
antibiot
includ
carbapenem
catalyz
hydrolyt
cleavag
substrat
amid
bond
basi
protein
sequenc
similar
three
differ
lineag
name
subclass
character
number
experiment
theoret
studi
also
devot
understand
structur
mechanist
properti
mbl
howev
sinc
novel
like
potent
extens
known
mbl
inactiv
blactam
antibiot
urgent
us
address
ligand
bind
properti
catalyt
mechan
order
light
road
develop
novel
antibiot
combat
emerg
posit
pathogen
explor
molecular
basi
antibiot
hydrolysi
homolog
model
method
perform
obtain
structur
molecular
dock
method
appli
obtain
bind
mode
antibiot
comparison
mbl
complex
also
investig
addit
catalyz
hydrolysi
variou
antibiot
substrat
monitor
follow
absorb
variat
result
open
blactam
ring
suggest
display
differ
resist
abil
differ
kind
antibiot
base
model
result
four
point
mutant
includ
made
enzymat
activ
measur
compar
wildtyp
significantli
decreas
activ
mutant
valid
accuraci
model
hand
shed
light
catalyt
mechan
novel
molecular
basi
first
time
furthermor
enzymat
activ
toward
differ
antibiot
test
studi
would
provid
clue
acceler
new
antibiot
design
posit
strain
studi
overal
structur
homolog
model
multipl
sequenc
align
shown
figur
among
subclass
cpha
subclass
subclass
highli
homolog
subclass
sequenc
ident
addit
sequenc
align
indic
contain
ident
coordin
residu
hishishi
zn
bind
site
aspcyshi
zn
ii
bind
site
subclass
impli
belong
subclass
mbl
accordingli
crystal
structur
pdb
id
use
templat
homolog
model
shown
figur
overal
structur
share
common
characterist
fold
abba
sandwich
resembl
architectur
featur
subclass
activ
site
highli
homolog
activ
site
figur
zn
coordin
three
conserv
histidin
residu
zn
ii
coordin
conserv
residu
exactli
consist
xray
crystal
structur
water
molecul
bridg
zinc
ion
act
nucleophil
blactam
hydrolysi
two
mobil
loop
activ
site
shown
figur
crucial
substrat
recognit
bind
catalysi
mbl
also
call
flap
loop
compos
amino
acid
ldmpgfgava
residu
compar
qsfdgavyp
size
activ
site
caviti
enlarg
less
bulki
amino
acid
suggest
broader
substrat
profil
besid
worth
note
hydrophob
other
one
benzen
ring
middl
sidechain
point
solvent
less
bulki
amino
acid
especi
glycin
propos
make
flexibl
substrat
bind
crystal
structur
complex
hydrolyz
ampicillin
pdb
id
repres
open
state
compar
model
crystal
structur
apo
pdb
id
display
semiclos
state
consequ
propos
undergo
signific
conform
chang
substrat
bind
differ
state
without
substrat
regard
prove
play
import
role
substrat
bind
catalysi
inhibit
hbond
interact
arginin
mutat
also
enlarg
size
activ
site
caviti
moreov
instead
probabl
play
similar
role
form
electrostat
interact
carboxyl
substrat
detail
comparison
two
loop
shown
figur
furthermor
two
residu
point
play
crucial
role
stabil
conform
activ
site
hbond
network
residu
hydrophob
interact
residu
besid
uniqu
residu
two
loop
n
terminu
longer
analogu
even
without
model
structur
specul
assist
pack
affect
hydrolyt
catalysi
also
contain
addit
insert
residu
present
mbl
sinc
insert
opposit
side
activ
site
distanc
around
role
hydrolysi
reaction
still
unknown
summari
uniqu
structur
characterist
probabl
contribut
potent
hydrolysi
broader
substrat
rang
novel
especi
bulkier
antibiot
degrad
mbl
structur
model
molecular
dock
studi
perform
two
report
effect
antibiot
tigecyclin
colistin
posit
strain
wellknown
antibiot
includ
carbapenem
report
destroy
posit
pathogen
dock
activ
site
molecular
dock
data
indic
latter
antibiot
fit
activ
site
quit
well
take
two
typic
antibiot
imipenem
carbapenem
exampl
dock
complex
structur
reveal
although
antibiot
adopt
divers
conform
activ
site
lactam
motif
posit
orient
coordin
zinc
ion
tightli
figur
suggest
catalyt
mechan
highli
conserv
among
subclass
enzym
shown
figur
substratebind
polar
lactam
bond
due
coordin
carbonyl
oxygen
zn
lactam
nitrogen
zn
ii
attack
water
oxygen
lead
oxyanion
stabil
zn
follow
subsequ
cleavag
cn
bond
lactam
nitrogen
expel
anion
stabil
coordin
zn
ii
act
gener
acid
last
step
proton
nitrogen
consid
ratelimit
controversi
step
date
compar
known
subclass
enzym
harbor
lysinerich
positivecharg
region
favor
proton
probabl
account
potent
catalyt
activ
least
part
notabl
colistin
report
antibiot
suscept
posit
pathogen
abl
fit
activ
site
well
probabl
due
bulki
volum
comparison
complex
structur
meropenem
meropenem
gain
structur
insight
mechan
potent
hydrolysi
intermolecular
interact
three
model
complex
antibiot
meropenem
compar
analyz
detail
figur
c
complex
structur
lactam
oxygen
carboxyl
oxygen
atom
coordin
zn
zn
ii
distanc
respect
addit
hbond
atom
n
lactam
oxygen
atom
distanc
also
contribut
polar
lactam
bond
meanwhil
water
molecul
bridg
two
zinc
ion
distanc
respect
serv
nucleophil
attack
atom
c
blactam
carbonyl
methyl
meropenem
form
hbond
atom
n
togeth
fact
rel
bulki
activ
site
caviti
caus
residu
variat
flexibl
potent
hydrolyz
bulkier
antibiot
differ
meropenem
strong
hbond
carboxyl
meropenem
moreov
form
hydrophob
interact
meropenem
dramat
reduc
size
activ
site
caviti
structur
hydrophob
interact
make
lactam
ring
rotat
elong
distanc
lactam
oxygen
zn
figur
consequ
shallow
activ
site
make
lactam
difficult
posit
proper
orient
catalysi
probabl
explain
weaker
activ
catalyz
antibiot
compar
contrast
share
littl
structur
similar
especi
flap
loop
conserv
lead
flat
activ
site
cleft
obvious
meropenem
mediat
interact
except
lactam
motif
figur
suggest
low
bind
affin
substrat
flexibl
characterist
make
antibiot
littl
access
proper
orient
hydrolysi
agreement
intermolecular
interact
model
enzym
antibiot
report
minim
inhibitori
concentr
meropenem
posit
ecoli
strain
mgml
posit
ecoli
strain
mgml
suggest
probabl
potent
antibiot
hydrolysi
besid
bind
mode
hydrolyz
antibiot
also
investig
take
hydrolyz
meropenem
exampl
figur
notic
origin
carboxyl
form
electrostat
interact
hydrophob
residu
form
stabl
hydrophob
interact
dimethylamino
group
appear
conform
antibiot
undergo
slight
exchang
catalysi
valid
result
extract
silico
studi
went
ahead
perform
wet
experi
explor
detail
molecular
basi
catalyt
mechan
firstli
construct
sumo
small
ubiquitinrel
modifi
tag
express
plasmid
overexpress
ecoli
strain
purifi
fusion
protein
nicolumn
affin
chromatographi
protein
releas
fusion
protein
ubiquitinlik
proteinspecif
proteas
proteas
cleavag
pure
protein
obtain
final
gel
filtrat
chromatographi
figur
b
c
secondli
catalyz
hydrolysi
variou
antibiot
substrat
monitor
follow
absorb
variat
result
open
blactam
ring
suscept
seven
typic
antibiot
assess
chemic
structur
antibiot
display
figur
shown
figur
rapidli
hydrolyz
carbapenem
antibiot
includ
meropenem
imipenem
harbor
moder
catalyt
hydrolysi
abil
cephalosporin
antibiot
includ
ceftazidim
cefotaxim
cefpirom
contrast
suscept
tigecyclin
monobactamaztreonam
similar
catalyt
abil
enterobacteriacea
explor
detail
mechan
suscept
two
antibiot
posit
strain
mm
meropenem
use
substrat
mm
mm
tigecyclin
aztreonam
mix
reaction
system
inhibitor
surprisingli
tigecyclin
probabl
display
certain
degre
inhibit
hydrolysi
veloc
meropenem
partial
slow
differ
concentr
tigecyclin
ad
reaction
system
figur
anoth
posit
strain
suscept
antibiot
aztreonam
nt
see
inhibitori
effect
favorit
substrat
data
shown
short
data
reveal
molecular
basi
novel
posit
strain
possess
potent
resist
carbapenem
hand
identifi
weak
inhibitortigecyclin
previous
report
inhibit
growth
harbor
klebsiella
pneumonia
work
may
pave
road
design
inhibitor
new
antibiot
suscept
meanwhil
base
model
design
follow
point
mutant
includ
activ
mutant
meropenem
measur
result
shown
figur
obviou
mutant
almost
complet
lose
activ
antibiot
hydrolysi
result
turn
verifi
accuraci
model
zn
ii
coordin
conserv
residu
spite
still
intrigu
whether
effect
structur
function
howev
decreas
catalyt
activ
impli
mechan
zn
ii
assist
support
propos
zn
ii
ion
crucial
stabil
develop
neg
charg
blactam
nitrogen
atom
show
figur
regard
mutant
significantli
decreas
hydrolysi
activ
indic
electrostat
interact
origin
carboxyl
group
hydrolyz
antibiot
positivecharg
sidechain
probabl
afford
one
drive
forc
catalysi
respect
ldmpgfgava
loop
displac
qsfdgavyp
differ
point
mutant
hydrolyt
catalysi
nt
decreas
compar
wildtyp
mean
chang
would
nt
affect
hydrolyt
catalysi
much
moreov
report
mutant
strongli
weaken
imipenem
hydrolysi
activ
prove
crucial
role
uniqu
ha
hq
motif
compar
hfhdd
motif
mbl
furthermor
sinc
critic
substrat
bind
catalysi
attent
would
paid
glycin
lysin
nowaday
antibiot
resist
gramneg
bacteria
alreadi
great
risk
public
health
newli
emerg
call
superbug
possess
potent
hydrolysi
abil
toward
almost
antibiot
henc
becom
new
threat
clinic
surgeri
one
typic
exampl
remark
abil
bacteria
adapt
eventu
becom
resist
new
antibiot
made
much
easier
exist
plasmid
transmit
easili
bacterium
bacterium
studi
structur
model
antibiot
complex
obtain
homolog
model
molecular
dock
method
detail
analysi
indic
flexibl
hydrophob
togeth
positivecharg
lead
potent
antibiot
hydrolysi
compar
mbl
meanwhil
experi
prove
highli
resist
carbapenem
cephalosporin
suscept
aztreonam
tigecyclin
firstli
impli
slow
hydrolysi
veloc
meropenem
studi
moreov
mutant
result
display
molecular
basi
catalyt
mechan
present
effect
antibiot
posit
pathogen
appreci
strategi
identifi
drug
candid
exist
antibiot
tigecyclin
base
model
use
structurebas
virtual
screen
eg
molecular
dock
ligandbas
receptorbas
pharmacophorebas
drug
design
conjunct
bioassay
strategi
use
success
discoveri
compound
cinanserin
sar
sever
acut
respiratori
syndrom
taken
togeth
studi
provid
clue
investig
molecular
basi
extend
antibiot
resist
shed
light
upon
discoveri
new
antibiot
posit
strain
clinic
studi
protein
sequenc
enterococcu
faecium
retriev
ncbi
http
wwwncbinlmnih
gov
protein
databas
blastp
program
perform
search
homologu
rcsb
protein
databank
accordingli
crystal
structur
pdb
id
select
templat
whose
sequenc
ident
analyz
sequenc
conserv
sequenc
align
cpha
perform
gap
insert
sequenc
find
optim
align
shown
figur
structur
model
use
insightii
softwar
accelri
inc
san
diego
ca
usa
optim
energi
minim
use
amber
forc
field
implement
sybyl
softwar
packag
minim
gradual
hydrogen
sidechain
use
constraint
heavi
backbon
atom
allevi
remain
bad
steric
contact
optim
structur
subject
evalu
procheck
examin
stereochem
qualiti
structur
ration
verifi
ration
structur
subject
subsequ
studi
glide
calcul
perform
maestro
schroding
inc
hydrogen
atom
charg
ad
brief
relax
perform
use
protein
prepar
modul
maestro
prepar
refin
option
restrain
partial
minim
termin
rootmeansquar
deviat
rmsd
reach
maximum
valu
order
reliev
steric
clash
gridenclos
box
center
zn
defin
enclos
residu
locat
within
scale
factor
set
van
der
waal
vdm
radii
receptor
atom
partial
atom
charg
less
dock
process
extraprecis
xp
dock
adopt
gener
minim
pose
glide
score
function
gscore
use
select
final
pose
antibiot
togeth
report
studi
reason
pose
use
bind
mode
analysi
antibiot
use
studi
purchas
j
k
scientif
ltd
except
kanamycin
purchas
sangon
biotech
shanghai
co
ltd
gene
obtain
bp
pcr
product
huashan
hospit
new
pcr
product
restrict
site
ndei
forward
site
xhoi
revers
site
encod
truncat
protein
amino
acid
last
amino
acid
design
construct
modifi
vector
result
express
fusion
protein
ntermin
sumo
small
ubiquitinrel
modifi
tag
quickchang
ii
sitedirect
mutagenesi
kit
stratagen
la
jolla
ca
use
introduc
mutat
includ
replac
residu
ldmpgfgava
correspond
residu
qsfdgavyp
gene
express
vector
transform
ecoli
strain
overnight
cultur
transform
bacteria
luriabertani
lb
medium
contain
mgml
kanamycin
use
inocul
liter
lb
medium
contain
mgml
kanamycin
mm
zncl
bacteria
cultur
shake
reach
optic
densiti
nm
transfer
induc
mm
iptg
overnight
bacteria
collect
centrifug
resuspend
ml
lysi
buffer
contain
mm
tri
ph
mm
nacl
bmercaptoethanol
per
liter
cultur
bacteria
ruptur
sonic
bacteria
debri
remov
centrifug
rpm
min
clear
supernat
load
onto
nicolumn
preequilibr
lysi
buffer
wash
lysi
buffer
supplement
mm
imidazol
ubiquitinlik
proteinspecif
proteas
add
nicolumn
digest
fusion
protein
overnight
collect
flow
concentr
load
onto
superdex
column
preequilibr
mm
tri
ph
mm
nacl
mm
dtt
fraction
contain
correspond
mutat
protein
pool
concentr
store
freezer
protein
puriti
estim
sodium
dodecyl
sulfat
sd
polyacrylamid
gel
electrophoresi
final
protein
concentr
determin
use
molar
extinct
coeffici
nm
cm
catalyz
substrat
hydrolys
reaction
carri
uvstarh
well
micropl
greiner
bioon
ltd
room
temperatur
within
reaction
buffer
mm
hepe
ph
antibiot
hydrolys
monitor
tecan
infinit
multimod
absorb
micropl
reader
tecan
group
ltd
peak
absorb
variou
antibiot
